The ADC binds HER2, is internalized, and releases the topoisomerase I inhibitor deruxtecan, causing DNA damage, cell-cycle arrest, and apoptosis in HER2+ cells; the IgG1 Fc can also engage ADCC, with a bystander effect from the membrane-permeable payload.